China
Every company in the roster headquartered in China.
Every company in the roster headquartered in China.
130 of 130 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Sciwind BiosciencesPrivate | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | ecnoglutidePhase 3 · ObesityReliable signal | 5 Jan 2027Ecnoglutide (VRB-101) · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 2 | ALK202Phase 2 · Non-Small Cell Lung Cancer | Dec 2027ALK202 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 3 | Edaravone (TTYP01)Phase 3 · Acute Ischemic Stroke | 23 Oct 2028Edaravone (TTYP01) · Phase 2 | — | — | — | — | |
| 1 asset: 1 Ph 3 | Sodium oligomannatePhase 3 · Alzheimer's DiseaseReliable signal | None on record | — | — | — | — | |
Shanghai HEP PharmaceuticalPrivate | 1 asset: 1 Ph 3 | hepalatidePhase 3 · Chronic Hepatitis Delta | Jun 2028hepalatide · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 2 | U32 CAR-TPhase 1/2 · Acute Myeloid Leukemia | 31 Dec 2027U32 CAR-T · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 3 | efsubaglutide alfaPhase 3 · Type 2 DiabetesReliable signal | 30 Apr 2027efsubaglutide alfa · Phase 1 | — | — | — | — | |
| 2 assets: 2 Ph 2 | INV-6452Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 4 Feb 2028INV-6452 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 2 | MS-553Phase 1/2 · Chronic Lymphocytic Leukemia | Sep 2028MS-553 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 Ph 1 | SIM0505Phase 1 · Non-Small Cell Lung Cancer | Feb 2028SIM0505 · Phase 1 | — | — | — | — | |
Sinotau Pharmaceutical GroupPrivate | 1 asset: 1 Ph 2 | XTR003Phase 2 · Heart Failure | 31 Dec 2026XTR003 · Phase 2 | — | — | — | — |
Suzhou AlphamabPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026Envafolimab · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 2 | LM103Phase 2 · Non-Small Cell Lung Cancer | 31 Dec 2027LM103 · Phase 2 | — | — | — | — | |
Suzhou NeuPharma Co., Ltd.Private | 1 asset: 1 Ph 2 | HLX208Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | BAY 3713372Phase 1/2 · Non-Small Cell Lung Cancer | 18 Jun 2029BAY 3713372 · Phase 1/2 | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 2 | PruvonertinibPhase 3 · Non-Small Cell Lung Cancer | None on record | — | — | — | — | |
Suzhou Siran BiotechnologyPrivate | 2 assets: 2 Ph 1 | SA030Phase 1 · Obesity | 30 Mar 2027SA1211 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record | — | — | — | — | |
Tianjin Hemay PharmaceuticalPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | MufemilastPhase 3 · Ulcerative ColitisPartial signal | None on record | — | — | — | — |
TrueLab BiopharmaceuticalPrivate | 1 asset: 1 Ph 1 | TL-003Phase 1 · Ulcerative Colitis | Apr 2027TL-003 · Phase 1 | — | — | — | — |
| 1 asset: 1 Ph 2 | TSN1611Phase 1/2 · Non-Small Cell Lung Cancer | 30 Oct 2027TSN1611 · Phase 1/2 | — | — | — | — | |
| 2 assets: 1 Ph 3, 1 Ph 1 | UBT251Phase 3 · Obesity | Dec 2026UBT251 · Phase 1 | — | — | — | — | |
Vincentage PharmaPrivate | 1 asset: 1 Ph 3 | VCT220Phase 3 · ObesityReliable signal | 1 Jul 2027VCT220 · Phase 2 | — | — | — | — |
WinHealth PharmaPrivate | 1 asset: 1 approved | Approved assets only | 15 Aug 2029Difelikefalin · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 3 | QR12000Phase 3 · HypertensionPartial signal | None on record | — | — | — | — | |
Yabao Pharmaceutical GroupPrivate | 1 asset: 1 Ph 2 | Globalagliatin HydrochloridePhase 2 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | VB19055Phase 2 · Hypertension | Dec 2027VB19055 · Phase 2 | — | — | — | — | |
Zensun (Shanghai) Sci & TechPrivate | 1 asset: 1 Ph 3 | Recombinant human neuregulin-1 (rhNRG-1)Phase 3 · Heart FailurePartial signal | None on record | — | — | — | — |
Zhejiang Doer BiologicsPrivate | 1 asset: 1 Ph 3 | DR10624Phase 3 · Severe HypertriglyceridemiaPartial signal | Apr 2028DR10624 · Phase 2 | — | $15.7BJun 2026 | ~18.0 qtrs | ~$2.4B |
Zhiyi PharmaceuticsPrivate | 1 asset: 1 Ph 2 | Live SK08Phase 2 · Ulcerative Colitis | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.